-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Exagen, Raises Price Target to $15

Benzinga·11/10/2025 11:51:29
Listen to the news
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $13 to $15.